Q-omics provides the consensus-scored MCM3AP profile across patient tissues and cancer cell-line models. MCM3AP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MCM3AP is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MCM3AP RNA expression shows 20,418 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where MCM3AP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCM3AP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCM3AP survival associations across molecular data types. MCM3AP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCM3AP RNA expression–survival associations across cancer types. High MCM3AP expression shows unfavorable associations in UVM, ACC, LIHC and CESC, but favorable associations in HNSC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MCM3AP RNA expression.
This table summarizes MCM3AP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MCM3AP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCM3AP shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, STAD and CHOL. The LIHC box plot shows higher MCM3AP RNA expression in tumor versus normal tissue (log2 FC = +1.183, t-test p < 0.001).
This table shows molecular features associated with MCM3AP in patient tissues and cancer cell lines. In patient samples, MCM3AP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MCM3AP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
